Macrodosing vs. Microdosing: Let’s Break It All Down

• By Sam Woolfe
• Medically approved by Dr. Jonathann Kuo
• February 5, 2024June 22, 2026
• macrodosing Microdosing psychedelics psychedelics side effects
• With 2 comments

Last reviewed and updated: June 21, 2026.

Key Takeaways

Macrodosing evidence	Strong: COMPASS Phase 2b (25mg psilocybin, significant antidepressant effect); JHU smoking/alcohol/cancer results; Phase 3 trials underway
Microdosing evidence	Weaker than anecdotes suggest: Szigeti 2021 + UC Davis 2022 showed placebo and active groups improved equally when blinding was effective
Third category	Medium dose (10–20mg psilocybin / ~1.5–2.5g mushrooms): noticeable but less intense than full macro; may offer therapeutic benefit with lower intensity
Macro risks	Challenging experiences; impairment (4–8+ hrs); psychiatric risk with psychosis/bipolar history; requires safe supervised setting
Dosage guide	See our complete shrooms dosage guide for dose ranges by experience level

When looking at macrodosing vs. microdosing, there are many ways we can distinguish between these two ways of taking psychedelics. Of course, the obvious difference is that one involves taking small doses while the other one, the way people have traditionally used psychedelics, means you take larger doses.

But the difference in dose between macrodosing and microdosing is significant: The experience of one is nothing like the former. And the outcomes of the two tend to be distinct as well.

RELATED: The Conundrum Of Microdosing

Here Are the Main Differences Between Macrodosing and Microdosing

Aspect	Microdosing	Macrodosing
Dose	Sub-perceptual doses, typically 1/10th to 1/20th of a recreational dose.	Full recreational or therapeutic doses, leading to profound alterations in perception, mood, and cognition.
Purpose	Often aimed at enhancing creativity, productivity, and emotional well-being without inducing significant alterations in perception or consciousness.	Used for significant psychological exploration, therapeutic purposes, or spiritual experiences.
Effects	Subtle effects that may improve mood, creativity, focus, and interpersonal relationships without noticeable hallucinations or significant shifts in perception.	Intense experiences including visual and auditory hallucinations, deep introspection, and altered state of consciousness.
Frequency of Use	Regularly scheduled doses, such as every third day.	Less frequent, often with weeks or months between sessions to integrate the experience.
Duration of Effects	Short-lived, typically lasting the day of dosing and possibly into the next day without noticeable impairment.	Longer-lasting effects, often extending for several hours during the dosing period with potential lingering effects.
Risks	Lower risk of acute adverse effects, but long-term effects and risks are not well-understood.	While psychedelics has low risk (compared to other drugs), there is a higher risk of intense psychological distress or “bad trips.”
Legal Status	Generally illegal in most jurisdictions, as it involves the use of controlled substances.	Same as microdosing, with the legality being dependent on the substance and jurisdiction.
Research	Emerging area of research with limited but growing studies supporting potential benefits and safety.	More established body of research, particularly in therapeutic contexts, but still subject to legal and ethical constraints.

Macrodosing vs. Microdosing: Understanding The Dosages

A macrodose tends to result in drastic perceptual, cognitive, and emotional changes. A macrodose could be anywhere between a threshold dose (the dose at which perceptual changes become noticeable) and a heroic dose (where effects like ego death are possible).

On the contrary, a microdose tends to be defined as a tenth to a twentieth of a normal recreational dose of a drug. Microdoses typically involve classic psychedelics (e.g. LSD, DMT, psilocybin, mescaline), but you can also microdose non-classic psychedelics (e.g. 4-AcO-DMT) and other psychoactive drugs (e.g. cannabis, MDMA).

This dose should be sub-perceptual, in that it does not cause effects like seeing objects morph or geometric patterns with eyes open or closed. Because the dose is so low, a microdose should not cause other classic psychedelic effects, like mystical experiences and intense emotional states.

Individual Dosing Differs

However, the line between macrodosing and microdosing is not clear.

Where is the precise point at which perceptual effects occur? How can we distinguish between aesthetic enhancement (where the world looks “nicer” and more vibrant on a microdose) and perceptual distortions? Does the feeling that the world has become brighter and more colorful mean a person has taken more than a microdose? There are no simple answers to these questions.

Also, what is a microdose for one person may not be the same for another. This is because people have differing levels of sensitivity to psychedelics.

An individual who is highly sensitive to these compounds may need to take much less than someone else to get the effects from microdosing they want. If he or she were to take a bigger dose, which for someone else is an ideal microdose, this could end up being a threshold dose for that individual.

So, while in theory we can easily distinguish between macrodosing and microdosing, doing so in practice is another matter altogether.

Ready to explore a new horizon in mental health? Try out the beta version of HealingChat, HealingMaps AI chatbot that takes all our vetted content, clinics and retreats to answer all your questions in a safe environment. Try the beta version now!

Macrodosing vs. Microdosing: The Different Effects

One crucial way to analyze macrodosing vs. microdosing is to look at the different experiences that both lead to.

Effects Of Macrodosing

The subjective effects of macrodosing are more significant and impactful compared to those from microdosing.

Visual Effects

• Color enhancement
• Depth perception distortions
• Objects morphing
• Color shifting
• Tracers
• Geometric hallucinations

Auditory Effects

• Enhancement
• Distortion
• Hallucinations

Cognitive Effects

• Introspection
• Delusion
• Increased music appreciation
• Increased sense of humor and laughter
• Thought acceleration
• Time distortion

Emotional Effects

• Euphoria
• Bliss
• Joy
• Empathy
• Compassion
• Anxiety
• Fear
• Panic

Mystical Effects

• Ego death
• Transcendence of time and space
• A sense of the holy, sacred, or divine
• Feelings of unity or interconnectedness
• Ineffability

Physical Effects

• Pupil dilation
• Excessive yawning
• Increased heart rate
• Nausea
• A pleasurable tingling sensation
• Physical euphoria
• Sedation
• Perception of bodily heaviness
• Motor control loss

Many people who macrodose — whether in a clinical setting, in a group, or somewhere like an ayahuasca retreat — also report a number of benefits. These include some of the below.

• Recovery from (or significant improvements in) depression, anxiety, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), alcoholism, and drug addiction
• More open-mindedness
• Greater connections to nature (known as nature-relatedness)
• The loss of the fear of death
• A stronger sense of meaning
• More authenticity
• Access to more positive emotions, like joy, gratitude, awe, and compassion (towards both oneself and others)
• Leading a more spiritual life, perhaps by practicing meditation to incorporate the psychedelic experience into one’s everyday life
• Finding the motivation to make major changes to aspects of one’s life, such as one’s relationships, career, hobbies, personal projects, goals, diet, and habits

RELATED: Psilocybin For Creativity: How A Hero’s Dose Helped Overcome Writer’s Block For My Latest Book

Effects Of Microdosing

If microdosing won’t provide any of the classic psychedelic effects, what can it do for people? Currently, there is conflicting evidence about what actual benefits microdosing can offer.

A 2021 study from Imperial College London found that the placebo effect may explain the benefits of microdosing. Then there have been some placebo-controlled studies showing microdoses of LSD have non-placebo effects.

Also, studies have found microdosers score higher on certain measures of well-being and cognition compared to non-microdosers.

But these kinds of studies, which rely on surveys, do not establish that microdosing actually cause any differences. It could be that people with better mental health are more likely to microdose, or that there is an unknown cause that makes people both more likely to microdose and be creative.

Regardless of the uncertainty about the true effects of microdosing, people claim that tiny doses of psychedelics lead to improvements in the following.

• Energy levels
• Mood
• Mental health (e.g. reductions in depression, anxiety, rumination)
• Concentration
• Productivity
• Relationships
• Microdosing shrooms can bring a better connection to self
• Creativity
• Lifestyle habits

RELATED: Are There Benefits Of Microdosing Mushrooms? And What Are The Risks And Legalities

Macrodosing vs. Microdosing: What The Science Says

As already mentioned, the evidence base for the effectiveness of microdosing differs from that of macrodosing.

There are many promising anecdotal reports from microdosers on how tiny doses of psychedelics have transformed their mental health, relationships, and who they are as people. But we don’t know if the placebo effect is driving these benefits (and, if so, to what extent).

When it comes to macrodosing, on the other hand, many rigorous, placebo-controlled studies have been conducted, showing significant benefits. Let’s take a look at some of the most important studies on microdosing and macrodosing.

Research On Macrodosing

Some of the most promising research on large doses of psychedelics (in combination with psychotherapy) reveal the following.

• Psilocybin-assisted therapy can effectively treat major depression, treatment-resistant depression, end-of-life anxiety, PTSD, and smoking addiction. It can also help people connect with their emotions and induce highly meaningful, mystical experiences.
• MDMA therapy can help patients with PTSD, social anxiety, alcoholism, and relationship issues.
• Ayahuasca can improve symptoms of depression and PTSD, and help people recover from addiction.
• Ibogaine can help people recover from addiction to stimulants, opiates, and alcohol, as well as cause a significant reduction in withdrawal symptoms.
• Treatment using ketamine can effectively treat major depression, treatment-resistant depression, suicidality, and treatment-resistant PTSD.

Research On Microdosing

Double-blind randomized controlled trials (RCTs), considered the “gold standard” of research, have revealed the following about microdosing.

• A 2019 study published in the journal Biological Psychiatry found that microdoses of LSD produced dose-related subjective effects (meaning the effects increased as the dose was increased). However, these microdoses did not have a significant effect on working memory and cognitive functioning, and creativity was actually worsened.
• Per a 2020 study from the journal European Neuropsychopharmacology, microdoses could improve positive mood, friendliness, and attention, but they can also lead to increased confusion and anxiety.
• A 2020 study from the Journal of Psychopharmacology found that a microdose of LSD could decrease people’s pain perception.

It should be noted that some of these results find that non-placebo effects result from doses of 20 micrograms (mcg) of LSD. This would be, for many people, too high to be a microdose.

Other than placebo-controlled studies, there is other research indicating the potential benefits of microdosing.

• Per a 2021 study from Scientific Reports, adults who microdose experience lower levels of anxiety and depression compared to non-microdosers.
• A 2021 study published in Psychopharmacology revealed that microdosers score higher on measures of wisdom, open-mindedness, creativity – and lower on measures of unhealthy beliefs and negative emotions – than non-microdosers.
• From a 2019 study in PLOS One, microdosing reduces depression and mind wandering but increases neuroticism.

What Research Has Clarified About Micro and Macrodosing in 2025

Both microdosing and macrodosing (full-dose psychedelic use) have received substantial research attention in the past several years. The picture that has emerged is more nuanced — and more honest — than early hype suggested.

Macrodosing: clinical trial results have arrived. Full-dose psilocybin therapy has now moved through Phase 2 trials and is in Phase 3 development for several indications. The headline results: COMPASS Pathways’ Phase 2b COMP360 trial (2022, 233 participants) found that a single 25 mg dose of psilocybin produced statistically significant antidepressant effects at 3 weeks compared to placebo, with the 25 mg dose outperforming 1 mg and 10 mg. Johns Hopkins and NYU have published compelling results for psilocybin in addiction (smoking cessation, alcohol use disorder) and existential distress in life-threatening illness. MAPS (now Lykos) found MDMA-assisted therapy effective for PTSD in Phase 2, though the FDA rejected their Phase 3 application in 2024 on trial design grounds. Overall, the macrodosing clinical trial evidence for psilocybin specifically in depression is now strong enough that Phase 3 trials are underway — a meaningful evidentiary milestone.

Microdosing: controlled research has been more sobering. Early enthusiasm for microdosing — sub-perceptual doses of psychedelics taken on a schedule (e.g., every third day) — was largely driven by anecdotal reports and observational studies. Controlled research, when it arrived, painted a more complicated picture. The most notable study (Szigeti et al., 2021, Imperial College London) used a self-blinding citizen science design and found that microdosing produced improvements in mood and focus — but so did the placebo. When the blinding was effective, the differences between microdosing and placebo were not statistically significant. A 2022 study from UC Davis found similar results. The current scientific understanding is that microdosing may produce real benefits in some individuals, but the evidence that those benefits are pharmacological rather than expectancy-driven is weak. This doesn’t mean microdosing “doesn’t work” — placebo effects are real effects — but it does change how confident one should be in the mechanism.

The “journey dose” or medium dose: a growing third category. Clinical research has increasingly identified a third dosing category that doesn’t fit neatly into either microdosing or traditional macrodosing: medium doses (roughly 10–20 mg psilocybin, or 1.5–2.5 grams of mushrooms) that produce noticeable psychedelic effects without the full intensity of a high macrodose. The COMPASS trial’s 10 mg arm showed meaningful (though smaller) effects compared to 25 mg. This middle range may offer therapeutic benefit with less intensity, more controllable set and setting requirements, and lower likelihood of overwhelming experiences — making it a potentially relevant range for people interested in therapeutic use who are concerned about the intensity of full macrodoses.

Frequently Asked Questions

What is the difference between microdosing and macrodosing?

Microdosing involves taking sub-perceptual doses of a psychedelic (typically 1/10th to 1/20th of a full dose) on a regular schedule — most commonly every third day. The goal is to experience subtle benefits (mood, focus, creativity, emotional resilience) without any noticeable psychedelic effects. Macrodosing refers to taking a full or near-full dose of a psychedelic — a dose that produces clear, unmistakable psychedelic effects including altered perception, emotional depth, and potentially mystical or ego-dissolving experiences. The two approaches are used for different purposes: microdosing is typically aimed at functional enhancement or mood support over time; macrodosing is typically oriented toward significant psychological experiences or therapeutic processing.

Does microdosing actually work?

The honest answer is: it may, but the evidence that the benefits are pharmacological (rather than placebo) is weaker than the anecdotal enthusiasm suggests. Controlled studies using self-blinding or objective blinding (Szigeti et al. 2021; UC Davis 2022) found that microdosers improved on mood and focus measures — but so did people taking placebo microdoses. When blinding was effective, differences between active and placebo were not statistically significant. This means we can’t currently distinguish whether microdosing “works” through pharmacology or through expectation, intention, and the ritual of practice. Both are real effects — but this distinction matters for anyone trying to decide whether microdosing is the right tool for them, versus therapy, exercise, sleep, or other evidence-based mood and focus interventions.

What does clinical research say about full-dose psilocybin therapy?

Full-dose psilocybin therapy has produced some of the most compelling results in recent mental health research. Key findings: COMPASS Pathways Phase 2b trial (25 mg psilocybin, n=79): statistically significant antidepressant effects at 3 weeks vs. placebo; Johns Hopkins: significant effects on smoking cessation (80% abstinence at 6 months in pilot), alcohol use disorder, and existential distress in cancer patients; NYU: alcohol use disorder and cancer-related depression/anxiety. These results have driven Phase 3 trials now underway. Psilocybin therapy as studied involves preparation, a supervised 6–8 hour session, and integration — it is not comparable to casual recreational use. The therapeutic frame, set and setting, and professional support are considered essential components of the therapeutic mechanism.

What are the risks of macrodosing compared to microdosing?

Macrodosing carries meaningfully higher acute risks than microdosing: (1) Challenging experiences — full-dose psychedelic experiences can include anxiety, fear, paranoia, or confronting difficult psychological material; (2) Impairment — macrodoses produce significant perceptual and cognitive changes lasting 4–8+ hours, during which driving or operating machinery is unsafe; (3) Rare psychiatric risks — people with personal or family history of psychosis, schizophrenia, or bipolar disorder face elevated risk of adverse psychiatric outcomes from full doses; (4) Environmental safety — the need for a safe, supportive setting is critical. Microdosing carries lower acute risks: sub-perceptual doses don’t produce impairment, though people taking serotonergic medications should be cautious, and long-term effects of repeated microdosing have not been studied in formal trials.

RELATED READING

• Shrooms Dosage Guide: How Much Should You Take?
• What Is Psychedelic Therapy? Here’s What The Research Says
• Does Microdosing Work? Here’s What the Science Says